Published in eLife, the study finds that a participant’s belief that they were taking a microdose was more influential on positive changes in mental health measures than the microdose itself.
Lead author of the study, Balázs Szigeti, writes, “Our findings confirm the anecdotal benefits of microdosing (improvements in a broad range of psychological measures); however, the results also suggest that the improvements are not due to the pharmacological action of microdosing, but are rather explained by the placebo effect.”
The Biggest Psychedelic Study to Date
The study in question is the largest placebo-controlled trial on psychedelics in modern research history, with 191 participants completing a 4-week regimen of microdosing. Previous studies on microdosing have, up until now, lacked a placebo-control due to logistical issues.
The researchers, however, cleverly utilised a citizen science initiative to both minimise the cost, and maximise the amount of data collected. Online volunteers, who already had the intention to microdose, were asked to participate in the study. If they were willing and able, the researchers sent out ‘self-blinding’ instructions – the volunteers provided the psychedelics themselves, and then distributed their microdose of choice (most likely LSD or psilocybin mushrooms) amongst placebo capsules in an envelope for each of the four weeks. Using QR codes, the experimenters knew what the participants took each day, while the volunteers were none-the-wiser.
The sample was split into three groups: a placebo group, a half-and-half, and a microdose group. The amount of microdoses received were scaled up in each group; the placebo group received none, the half and half group received four, and the microdose group received eight.
In order to assess the effects of microdosing on their cognitive abilities, the volunteers had to complete a battery of tests every few days. In addition to this, the microdosers also filled out questionnaires relating to their mental health, assessing the severity of depression, anxiety, and wellbeing amongst other measures. The authors predicted that on the days that the participants actually received the microdose, these measures of mental health, and cognitive performance, would significantly increase.
Looking at the microdose group alone, the results supported the anecdotal benefits of microdosing; participants in the microdose group showed a significantly positive increase in mental health after the four-week regimen. However, the researchers failed to find a significant difference between the placebo group and the microdose group, making any positive changes in the microdose condition likely due to placebo effects.
To strengthen this conclusion, the researchers also found that the participants who reportedly thought they were taking a microdose yielded higher scores on mental health measures, regardless of what they were actually taking. That is, if the participant was taking a placebo, but guessed they were taking a microdose, their mood would significantly improve. Moreover, if the participant was taking a microdose, but guessed they were taking a placebo, there was no positive improvement.
Szigeti concludes, “…these results strongly suggest that the actual content of capsules did not determine differences between the conditions, but beliefs about their content did.”
The Future of Microdosing
Despite the ingenious application of citizen science, the study comes with some pitfalls. Mainly, the researchers were not able to verify the purity of the microdoses, nor were they able to standardise the amount that volunteers took.
However, conducting the largest placebo-controlled psychedelic study is no mean feat, and a major milestone for psychedelic science. While the results may be a surprise to many — anecdotal evidence in the psychedelic space has been loud and clear — scientific researchers may maintain cautious skepticism about the effects of microdosing. The placebo effect is very powerful and even surprised many volunteers within the study.
One testified, “I have just checked the remaining envelopes and it appears that I was indeed taking placebos throughout the trial. I’m quite astonished […] It seems I was able to generate a powerful ‘altered consciousness’ experience based only [on] the expectation around the possibility of a microdose.”
Moreover, the research comes at an important time. As more and more companies are seeking to sell microdosing kits and courses, there needs to be properly conducted scientific research that backs up the claims around the alleged benefits of microdosing.
However, these results do not denounce the positive effects of other sized doses of psychedelics. There is still much to explore and research in how these powerful substances can benefit mental health and wellbeing.
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.